Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by toinv261on Aug 03, 2015 10:29am

74 Views

Post# 23984571

RE:RE:RE:RE:gv...MACE vs. QoL vs. Lipitor-Crestor or 208...

Hi GV.

Interesting and helpful layout. I guess that is why it takes so much time to get the trial designed. My unerstanding was that the selection is a series of "and" conditions. e.g. They will be on Crestor or Lipitor (e.g. being treated for high LDL) AND they will have diabetes or pre diabetes AND they will have low HDL AND they may have had or be at risk for some CVD (e.g. heart attack, stroke, hypertension, etc).

Always interesting to learn through sharing ideas.

Cheers
Toinv :)

Bullboard Posts

Bitcoin company adds convenience of modern banking